Pfizer Internal and External Analysis

One primary goal of Pfizer is to deliver sustained, excellent product by outperforming Pfizer’s competitors and must differentiate itself adequately from its competitors. Competitive advantage is central to strategic management in that it will produce and sustain superior performance. To be competitive in a business environment, often it requires the company to have a product or service different and better than other organizations competing in the same marketplace. According to Wadman (2007) “Pfizer and the rest of the pharmaceutical industry need to develop more sophisticated drugs, targeted at a smaller number of people more quickly, efficiently and at a lower cost” (p. 1). Once Pfizer’s strengths, weaknesses, opportunities, and threats are assessed and analyzed, managers must decide a set of strategies to reduce or eliminate its weaknesses and capitalize on its strengths and maximize opportunities. An example is Porter’s three generic strategy approaches of differentiation, cost leadership, and focus strategy by using differentiation strategies to differentiate Pfizer from its competitors. Strategies are essential; however, it is useless unless they are effectively implemented levels of the company. Business-level strategies are typically developed and implemented by heads of business units and are first approved by top management. The functional level strategy is the last level that focuses on developing strategies for managing the various departments to

Pfizer is the largest American pharmaceutical company and one of the largest pharmaceutical companies in the world. It competes with Merck and Glaxo, and markets such well-known medications as Celebrex and Viagra. However, the pharmaceutical industry as a whole has undergone changes in recent years with significant consolidation taking place and with increased scrutiny regarding the ways in which drugs are developed, tested and marketed. In addition, recent controversies have erupted regarding Merck's drug Vioxx, and Pfizer has been the target of unwanted publicity regarding its painkiller Celebrex. This research considers the strategic position of Pfizer, including its strengths and weaknesses as well

The pharmaceutical industry is considered to be on of the fastest growing sectors in America. The IMS Institute for Healthcare Informatics reported revenues of $424.8 billion in 2015, a 12.2 percent increase from last year (pharma commerce). Furthermore, the U.S. pharmaceutical industry is considered to be a worldwide leader with sales accounting for approximately 44.5 percent of global sales (Whiteside, 2016). The driving force of these revenue figures is Big Pharma –the largest pharmaceutical companies in the United States. In fact, Pfizer, Merck & Co., and Johnson and Johnson [J&J] are three American companies ranked at the top of the global pharmaceutical market (Dezzanni, 2016).

The pharmaceutical industry includes companies that research, develop, market or distribute generic and branded drugs. The industry expanded during the 1980’s and drugs to treat heart disease and AIDS were prominent. Consumer demand for nutritional supplements and alternative medicine increased during the 1990’s with the Internet facilitating direct purchases of drugs. Advertising for direct consumption of pharmaceutical drugs became more prominent; pharmaceutical companies were criticized for over medicating personality or social problems.

Pfizer operates with high and sustainable gross margin, above the industry average. Though there is a reduction in revenues in 2013 compared to 2012, whereas COGS stays almost at the same level. The main reason of revenue reduction is the loss of exclusivity of branded Lipitor, Geodon and other drugs (approximately $ 3.9 billion), whereas revenue growth from other

Pfizer is a pharmaceutical company ranking number one in sales in the world. The company is based in New York City, with its research headquarters in Groton, Connecticut. Its headquarters are in Midtown Manhattan, New York City. Pfizer owes a lot of its success to

There are two main operational strategic issues that Eli Lilly will face: the war on patents and the golden pipeline. These operational issues go hand in hand with each other. Taking a look at the golden pipeline, this an area that can either kill or bring a pharmaceutical company to stardom. There is a choice that pharmaceutical companies need to make: either create a different drug that is more effective for something that is already produced or create something new that has not been on the market before. Eli Lilly needs to strategically think of where they want to be and how their pipeline will align with their vision: “We will make a significant contribution to humanity by improving global health in the 21st century” (Eli Lilly About).

It is an honor for me to lead Pfizer at this important time for both our company and the industry. I’ve spent my entire career at Pfizer and during this time I have seen the industry change and evolve in terms of customers’ needs, regulatory standards and where growth occurs. Among these changes, one of the most important has been the increasing pressure from payers, governments and society to deliver greater value. That’s why I believe there is a fundamental question facing the industry and Pfizer. Simply stated, it is: Do we have a research model that will consistently produce results that improve the lives of patients

Pfizer is one of the largest pharmaceutical corporations in the world and is the manufacture of many popular drugs including Advil. On the other hand Allergan is a smaller pharmaceutical corporation based in Ireland known for making Botox. So, in late October 2015 Pfizer was on the verge of acquiring fellow pharmaceutical company Allergan in a $160 billion dollar deal. Pfizer was intrigued about acquiring Allergan because the deal would have allowed Pfizer to relocate its headquarters from New York City to Ireland and in turn benefit from their corporate tax rate lower tax

* Competitive Pricing – Merck is sometimes forced to lower prices of products, either ones that have gone off patent to maintain market share in the product, as well as for products that are still on patent in order to compete with rival products for the same treatment that are marketed by competitors

In summary of the Pfizer case study, the organization realized executives and key employees were spending 20-40% of their time on support work rather than knowledge work. In response, the company started a “magic button” process. When an employee would like to pass off the tasks that are monotonous or lack luster they can press the “magic button”. The tasks are assigned to individuals of an outside organization for completion. The result is an increase of employee productivity.

Pfizer is known as one of the first and one of the world’s largest Pharmaceutical company that was establish in 1849. It was founded by two cousins called Charles Pfizer and Charles F. Erhart in New York City. Pfizer was as a manufacturer for fine chemicals but because of the discovery that was made in 1950 which made the company the path towards becoming the research-based pharmaceutical that it is update. The product that was first produced was the palatable form of sautonin which was used to treat intestinal worm. The Headquarters of Pfizer is located in New York City, with its research headquarters in Groton, Connecticut, which is nowadays the top multinational corporation that is sold all over the world. It is ranked as the second in the US and Japan market, and Novartis in first place and Roche in third place. The Pfizer Inc. is consisted with a trademark that is called PFIZER. Because of Pfizer’s strategies, Pfizer

Technological Opportunities: Online ordering. Pfizer’s excellent supply chain management system allows them to get prescriptions and medications to end users safely and efficiently worldwide.

An analysis of the Pfizer business model is important to find present and probable future inefficiencies that they may be improved. The business culture, although having great

With the acquisition of Wyeth, Pfizer was provided with an influx of 17 new drugs and vaccines including Effexor and Enbrel followed with the launch of five new drugs in 2013, such as Axitinib (for kidney cancer treatment); Tofacitinib (arthritis) and Prevnar (pneumonia), among others. These launches and influx should help Pfizer compete with more